Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
20001.7k citationsFrances A. Shepherd, Janet Dancey et al.Journal of Clinical Oncologyprofile →
Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer
1999694 citationsFrances A. Shepherd, Richard J. Gralla et al.Journal of Clinical Oncologyprofile →
The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
2003593 citationsPaul J. Hesketh, Steven M. Grunberg et al.Journal of Clinical Oncologyprofile →
Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and Vomiting
1981555 citationsRichard J. Gralla, Loretta M. Itri et al.profile →
American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
2006516 citationsMark G. Kris, Paul J. Hesketh et al.Journal of Clinical Oncologyprofile →
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
1999483 citationsRichard J. Gralla, Mark G. Kris et al.Journal of Clinical Oncologyprofile →
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma
2017405 citationsRichard J. Gralla et al.profile →
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
2016397 citationsFausto Roila, Jørn Herrstedt et al.profile →
Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
2013383 citationsRichard J. Gralla et al.profile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Richard J. Gralla
Since
Specialization
Citations
This map shows the geographic impact of Richard J. Gralla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard J. Gralla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard J. Gralla more than expected).
Fields of papers citing papers by Richard J. Gralla
This network shows the impact of papers produced by Richard J. Gralla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard J. Gralla. The network helps show where Richard J. Gralla may publish in the future.
Co-authorship network of co-authors of Richard J. Gralla
This figure shows the co-authorship network connecting the top 25 collaborators of Richard J. Gralla.
A scholar is included among the top collaborators of Richard J. Gralla based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Richard J. Gralla. Richard J. Gralla is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Shepherd, Frances A., Janet Dancey, Rodryg Ramlau, et al.. (2000). Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy. Journal of Clinical Oncology. 18(10). 2095–2103.1717 indexed citations breakdown →
Gralla, Richard J.. (1991). Progress in the development of antiemetics for chemotherapy-induced nausea and vomiting. 43(5). 407–411.2 indexed citations
Gralla, Richard J.. (1982). Non-small cell lung cancer and vindesine: A review. 8(5). 565–570.1 indexed citations
14.
Chapman, Robert, David P. Kelsen, & Richard J. Gralla. (1981). Phase II trials of methylglyoxal bis (guanylhydrazone) (MGBG) in 3 solid tumors. Proceedings of the American Association for Cancer Research. 22.2 indexed citations
15.
Itri, Loretta M., Richard J. Gralla, & E. S. Casper. (1981). Vindesine with cisplatin in non-small lung cancer (NSCLC): The influence on survival and the effect of adding conventional agents. Proceedings of the American Association for Cancer Research. 22.1 indexed citations
16.
Gralla, Richard J., et al.. (1981). High dose metoclopramide: Effective antiemetic against cisplatin (DDP) in randomized trials VS. placebo and prochlorperazine (PCP). Proceedings of the American Association for Cancer Research. 22.2 indexed citations
17.
Itri, Loretta M., Richard J. Gralla, & David P. Kelsen. (1981). VP-16-213: A phase II study of non-small cell lung cancer (NSCLC). Proceedings of the American Association for Cancer Research. 22.2 indexed citations
18.
Casper, E. S., Richard J. Gralla, & Robert B. Golbey. (1979). Vindesine (DVA) and cis-dichlorodiammineplatinum II (DDP) combination chemotherapy in non-small cell lung cancer (NSCLC). Proceedings of the American Association for Cancer Research. 20.6 indexed citations
19.
Gralla, Richard J., Esteban Cvitkovic, & Robert B. Golbey. (1978). Cisdichlorodiammineplatinum II (DDP), adriamycin and cyclophosphamide combination chemotherapy in advanced non-small cell bronchogenic carcinoma. Proceedings of the American Association for Cancer Research. 19.5 indexed citations
20.
Gralla, Richard J., Esteban Cvitkovic, & Robert Golbey. (1977). Intensive chemotherapy with high dose cyclophosphamide and methotrexate with citrovorum rescue in advanced lung cancer. Proceedings of the American Association for Cancer Research. 18.1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.